awmsg logo



adalimumab (Humira®)


Reference No. 2571

Publication date:
10/12/2015


Appraisal information

adalimumab (Humira®) 40 mg/0.8 ml solution for injection


Company: AbbVie Ltd
BNF category: Skin
NMG meeting date: 07/10/2015
AWMSG meeting date: 11/11/2015
   
   
Submission Type: Limited Submission
Status: Recommended with restrictions
Advice No: 3615
Ministerial ratification: 09/12/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Adalimumab (Humira®) is recommended as an option for restricted use within NHS Wales for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to, or are inappropriate candidates for, topical therapy and phototherapies. Prescribing should be restricted to clinical situations as specified within the National Institute for Health and Care Excellence (NICE) guidance for adults.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download